3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2/3
1
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Sarcoma
76
Gastrointestinal Stromal Tumors
36
Dendritic Cell Sarcoma, Interdigitating
22
Glioblastoma
20
Liposarcoma
19
Gliosarcoma
19
Neoplasms
18
Leiomyosarcoma
16
Bone Neoplasms
16
Rhabdomyosarcoma
15
Neoplasm Metastasis
15
Lymphoma, Large B-Cell, Diffuse
15
Burkitt Lymphoma
15
Central Nervous System Neoplasms
14
Sarcoma, Synovial
13
Recurrence
13
Precursor Cell Lymphoblastic Leukemia-Lymphoma
13
Osteosarcoma
13
Hemangiosarcoma
12
Fibrosarcoma
12
Multiple Myeloma
11
Lymphoma, Non-Hodgkin
11
Lymphoma, Mantle-Cell
11
Lymphoma, Large-Cell, Immunoblastic
11
Lymphoma, Follicular
11
Lymphoma, B-Cell, Marginal Zone
11
Lymphoma
11
Leukemia, Myeloid, Chronic-Phase
11
Leukemia, Myeloid, Acute
11
Leukemia, Myeloid, Accelerated Phase
11
Interventions
Temozolomide
1
Irinotecan
1
FANG vaccine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Neoplasms, Connective Tissue
×
Sarcoma
×
Clear all
NCT03495921
2023-04-26
VITA
Gradalis, Inc.
Phase 3
Terminated
32 enrolled
13 charts